Company Overview and News


Add RARE
to your dashboard

Headline News

RARE / Ultragenyx Pharmaceutical Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-11 fintel.io
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has 157 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,117,142 shares. Largest shareholders include Wellington Management Group Llp, Capital International Investors, Capital Research Global Investors, BlackRock Inc., Fmr Llc, Vanguard Group Inc, Price T Rowe Associates Inc /md/, Columbia Wanger Asset Management Llc, State Street Corp, and Pictet Asset Management Ltd. (55-0)

Ultragenyx Announces Interim Data from Early Stage Study

2018-01-08 zacks
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) announced positive interim data from the first dose cohort of the phase I/II study on its adeno-associated virus (“AAV”) gene therapy candidate, DTX301. The study is evaluating DTX301 as a treatment for ornithine transcarbamylase (“OTC”) deficiency, the most common urea cycle disorder, which increases concentration of ammonia in blood. (98-0)

30 Big Biotech Events Coming in 2018

2017-12-31 247wallst
Over the past year, biotech companies have more or less kept pace with the markets, but they have the potential to break out in 2018. While they have been the obvious beneficiaries of a raging bull market, there have been plenty of factors that have held biotechs back as well. (285-7)

Adverum: Why This ~$3.50 Biotech 'Busted IPO' Gets Our 'Thumbs Up'

2017-12-29 seekingalpha
Although early-stage, the one-time administration feature of its therapies for A1AT deficiency, Hereditary Angioedema, and wet AMD, could completely disrupt the treatment landscape, obviating all current standard-of-care therapies. (44-2)

Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering

2017-12-19 seekingalpha
Today we will focus on Ultragenyx Pharmaceutical (RARE). The company announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis (NVS) for $130 million. (215-1)

Ultragenyx Looks To Treat Rare Bone Disease

2017-12-08 seekingalpha
Positive phase 3 data in patients with XLH serves as a boost for the upcoming PDUFA date set for April 9, 2017. (12-0)

Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars

2017-12-07 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day earlier. (273-3)

Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

2017-12-06 zacks
This week, companies like Amgen (AMGN - Free Report) , Revance Therapeutics, Inc. (RVNC - Free Report) and AbbVie (ABBV - Free Report) were in the news. While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates. Recap of the Week’s Most Important Stories Revance Soars on RT002 Data: Revance’s shares shot up 33. (318-0)

Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result

2017-12-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day earlier. (402-2)

Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

2017-11-22 zacks
Pipeline and regulatory updates were the focus this week with Ultragenyx Pharmaceutical (RARE - Free Report) gaining FDA approval for its first drug while companies like Cytokinetics (CYTK - Free Report) and Acorda Therapeutics (ACOR - Free Report) were hit by pipeline setbacks. Recap of the Week’s Most Important Stories Ultragenyx Gets FDA Approval for Rare Genetic Disease Drug: Ultragenyx gained FDA approval for its first drug, Mepsevii (vestronidase alfa), for the treatment of children and adults with mucopolysaccharidosis VII (MPS 7), also known as Sly syndrome. (201-0)

Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

2017-11-17 zacks
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) announced that the FDA has approved its genetic disorder drug, vestronidase alfa or rhGUS, for treatment of children and adults with mucopolysaccharidosis VII (MPS VII, also known as Sly syndrome). It is approved under the trade name, MEPSEVII. (43-0)

Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles

2017-11-16 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (381-9)

BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301

2017-11-16 reuters
* Ultragenyx announces completion of patient dosing in first cohort of phase 1/2 clinical study of dtx301 gene therapy in ornithine transcarbamylase (OTC) deficiency (12-0)

BRIEF-ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

2017-11-15 reuters
* ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII (12-0)

CUSIP: 90400D108